{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:14:33Z","timestamp":1789748073620,"version":"4.0.1"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.ctrv.2021.102180","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T06:05:40Z","timestamp":1616047540000},"page":"102180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":184,"special_numbering":"C","title":["Treatment landscape of metastatic pancreatic cancer"],"prefix":"10.1016","volume":"96","author":[{"given":"Sara","family":"De Dosso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander R.","family":"Siebenh\u00fcner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Winder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Fritsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoforos","family":"Astaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Szturz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Borner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2021.102180_b0005","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.3390\/ijms20184543","article-title":"Current clinical strategies of pancreatic cancer treatment and open molecular questions","volume":"20","author":"Brunner","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2021.102180_b0010","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2021.102180_b0015","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1080\/0284186X.2016.1197419","article-title":"More deaths from pancreatic cancer than breast cancer in the EU by 2017","volume":"55","author":"Ferlay","year":"2016","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctrv.2021.102180_b0020","doi-asserted-by":"crossref","first-page":"10","DOI":"10.14740\/wjon1166","article-title":"Epidemiology of pancreatic cancer: global trends, etiology and risk factors","volume":"10","author":"Rawla","year":"2019","journal-title":"World J Oncol"},{"key":"10.1016\/j.ctrv.2021.102180_b0025","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000\u201314 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries","volume":"391","author":"Allemani","year":"2018","journal-title":"The Lancet"},{"key":"10.1016\/j.ctrv.2021.102180_b0030","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2021.102180_b0035","unstructured":"American Cancer Society. Cancer Facts & Figures 1999\u20132020, https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/cancer-facts-figures-2020.html; 2020 (accessed 5 March 2021)."},{"key":"10.1016\/j.ctrv.2021.102180_b0040","first-page":"328","article-title":"Trends in pancreatic cancer survival in Switzerland","volume":"42013","author":"Montemurro","year":"2013","journal-title":"Schweiz Krebsbulletin Nr"},{"key":"10.1016\/j.ctrv.2021.102180_b0045","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2021.102180_b0050","unstructured":"BFS. Swiss National Cancer Statistics - Fact sheet, https:\/\/www.bfs.admin.ch\/bfs\/en\/home\/statistics\/health\/surveys\/ke.assetdetail.6706410.html; 2018 (accessed 5 March 2021)."},{"key":"10.1016\/j.ctrv.2021.102180_b0055","unstructured":"BFS. Cancer, https:\/\/www.bfs.admin.ch\/bfs\/en\/home\/statistics\/health\/state-health\/diseases\/cancer.html; 2020 (accessed 5 March 2021)."},{"key":"10.1016\/j.ctrv.2021.102180_b0060","unstructured":"Swiss cancer report 2015 - Current situation and developments. https:\/\/www.bfs.admin.ch\/bfs\/en\/home\/statistics\/health.assetdetail.428987.html; 2016 (accessed 5 March 2021)."},{"key":"10.1016\/j.ctrv.2021.102180_b0065","unstructured":"National statistics on cancer incidence NICER. https:\/\/www.nicer.org\/en\/statistics-atlas\/cancer-incidence (accessed 5 March 2021)."},{"key":"10.1016\/j.ctrv.2021.102180_b0070","first-page":"141","article-title":"Epidemiology and risk factors of pancreatic cancer","volume":"89","author":"Capasso","year":"2018","journal-title":"Acta Bio Medica Atenei Parm"},{"key":"10.1016\/j.ctrv.2021.102180_b0075","series-title":"AJCC cancer staging manual","author":"Amin","year":"2017"},{"key":"10.1016\/j.ctrv.2021.102180_b0080","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.3748\/wjg.v24.i43.4846","article-title":"Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes","volume":"24","author":"McGuigan","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ctrv.2021.102180_b0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0230060","article-title":"The impact of metastatic sites in advanced pancreatic adenocarcinoma, systematic review and meta-analysis of prospective randomized studies","volume":"15","author":"Us\u00f3n","year":"2020","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2021.102180_b0090","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.cell.2011.11.060","article-title":"Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies","volume":"148","author":"Haeno","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2021.102180_b0095","first-page":"52","article-title":"Precision oncology for hepato-pancreato-biliary (HPB) cancers: state of the art and future directions","author":"Akhoundova","year":"2020","journal-title":"Heal TIMES Oncol Hematol"},{"key":"10.1016\/j.ctrv.2021.102180_b0100","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/annonc\/mdz233","article-title":"Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"30","author":"Stjepanovic","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2021.102180_b0105","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2021.102180_b0110","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial","volume":"389","author":"Neoptolemos","year":"2017","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.ctrv.2021.102180_b0115","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jama.2013.279201","article-title":"Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial","volume":"310","author":"Oettle","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ctrv.2021.102180_b0120","unstructured":"ESMO Guidelines Committee. eUpdate \u2013 Cancer of the Pancreas Treatment Recommendations, https:\/\/www.esmo.org\/guidelines\/gastrointestinal-cancers\/pancreatic-cancer\/eupdate-cancer-of-the-pancreas-treatment-recommendations; 2019 [accessed 5 March 2021]. n.d."},{"key":"10.1016\/j.ctrv.2021.102180_b0125","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1200\/JCO.2020.38.15_suppl.4505","volume":"38","author":"Ghaneh","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102180_b0130","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1200\/JCO.2021.39.3_suppl.377","article-title":"Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas","volume":"39","author":"Katz","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102180_b0135","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102180_b0140","unstructured":"Gemcitabin Labatec\u00ae. Product information. Swissmedic, https:\/\/www.swissmedicinfo.ch; 2019 (accessed May 20, 2020)."},{"key":"10.1016\/j.ctrv.2021.102180_b0145","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2021.102180_b0150","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2147\/OTT.S124097","article-title":"nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial","volume":"10","author":"Tabernero","year":"2017","journal-title":"OncoTargets Ther"},{"key":"10.1016\/j.ctrv.2021.102180_b0155","doi-asserted-by":"crossref","first-page":"469","DOI":"10.21037\/jgo.2016.01.03","article-title":"Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial","volume":"7","author":"Scheithauer","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.ctrv.2021.102180_b0160","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju413","article-title":"nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III Trial. JNCI","volume":"107","author":"Goldstein","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2021.102180_b0165","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/cam4.2705","article-title":"Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: a population-based propensity score-weighted analysis","volume":"9","author":"Chan","year":"2019","journal-title":"Cancer Med"},{"issue":"30103\u20134","key":"10.1016\/j.ctrv.2021.102180_b0170","article-title":"Choice of first line systemic treatment in pancreatic cancer among national experts","volume":"S1424\u20133903","author":"Glatzer","year":"2020","journal-title":"Pancreatol Off J Int Assoc Pancreatol IAP Al"},{"key":"10.1016\/j.ctrv.2021.102180_b0175","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/MPA.0000000000001455","article-title":"Liposomal Irinotecan + 5-FU\/LV in metastatic pancreatic cancer","volume":"49","author":"Macarulla Mercad\u00e9","year":"2020","journal-title":"Pancreas"},{"key":"10.1016\/j.ctrv.2021.102180_b0180","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919875568","article-title":"An update on treatment options for pancreatic adenocarcinoma","volume":"11","author":"Lambert","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ctrv.2021.102180_b0185","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000587","article-title":"First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study","volume":"5","author":"Taieb","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2021.102180_b0190","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/bjc.2015.328","article-title":"Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort","volume":"113","author":"Portal","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2021.102180_b0195","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920905408","article-title":"Systematic review and meta-analysis of gemcitabine-based chemotherapy after FOLFIRINOX in advanced pancreatic cancer","volume":"12","author":"de Jesus","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ctrv.2021.102180_b0200","doi-asserted-by":"crossref","first-page":"806","DOI":"10.21037\/jgo.2018.06.08","article-title":"Retrospective analysis of efficacy and safety of Gemcitabine-based chemotherapy in patients with metastatic pancreatic adenocarcinoma experiencing disease progression on FOLFIRINOX","volume":"9","author":"de Jesus","year":"2018","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.ctrv.2021.102180_b0205","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1200\/JCO.2013.53.6995","article-title":"Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial","volume":"32","author":"Oettle","year":"2014","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102180_b0210","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1200\/JCO.2016.68.5776","article-title":"PANCREOX: a randomized phase III study of fluorouracil\/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy","volume":"34","author":"Gill","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102180_b0215","unstructured":"Onivyde\u00ae. Product information. Swissmedic, https:\/\/www.swissmedicinfo.ch; 2019 (accessed 5 March 2021)."},{"key":"10.1016\/j.ctrv.2021.102180_b0220","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam","year":"2016","journal-title":"The Lancet"},{"key":"10.1016\/j.ctrv.2021.102180_b0225","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejca.2018.09.029","article-title":"Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin","volume":"106","author":"Hubner","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2021.102180_b0230","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2018.12.007","article-title":"NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors","volume":"108","author":"Wang-Gillam","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2021.102180_b0235","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jgo.2019.02.011","article-title":"Liposomal irinotecan and 5-fluorouracil\/leucovorin in older patients with metastatic pancreatic cancer \u2013 A subgroup analysis of the pivotal NAPOLI-1 trial","volume":"10","author":"Macarulla","year":"2019","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.ctrv.2021.102180_b0240","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000504471","article-title":"Sequential treatment of metastatic adenocarcinoma of the pancreatic duct with liver metastasis following the NAPOLI-1 study protocol with nal-irinotecan plus 5-FU in the second line","volume":"13","author":"Akhoundova Sanoyan","year":"2020","journal-title":"Case Reps Oncol"},{"key":"10.1016\/j.ctrv.2021.102180_b0245","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919853196","article-title":"A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid","volume":"11","author":"Kieler","year":"2019","journal-title":"Ther Adv Med Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2021.102180_b0250","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.3390\/cancers12051131","article-title":"Multicenter retrospective analysis of second-line therapy after gemcitabine plus nab-paclitaxel in advanced pancreatic cancer patients","volume":"12","author":"Merz","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ctrv.2021.102180_b0255","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/MPA.0000000000001479","article-title":"Real-world dosing patterns and outcomes of patients with metastatic pancreatic cancer treated with a liposomal irinotecan regimen in the United States","volume":"49","author":"Barzi","year":"2020","journal-title":"Pancreas"},{"key":"10.1016\/j.ctrv.2021.102180_b0260","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1002\/ijc.31751","article-title":"Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma","volume":"144","author":"Hegewisch-Becker","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2021.102180_b0265","doi-asserted-by":"crossref","first-page":"4661","DOI":"10.1158\/1078-0432.CCR-20-0395","article-title":"Plasma IL8 is a biomarker for TAK1 activation and predicts resistance to nanoliposomal irinotecan in patients with gemcitabine-refractory pancreatic cancer","volume":"26","author":"Merz","year":"2020","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ctrv.2021.102180_b0270","first-page":"36","article-title":"TAK-ing aim at chemoresistance: the emerging role of MAP3K7 as a target for cancer therapy","volume":"33\u201335","author":"Santoro","year":"2017","journal-title":"Drug Resist Updat Rev Comment Antimicrob Anticancer Chemother"},{"issue":"8","key":"10.1016\/j.ctrv.2021.102180_b0275","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3390\/cancers11081068","article-title":"Nomogram for predicting survival in patients treated with liposomal irinotecan plus fluorouracil and leucovorin in metastatic pancreatic cancer","volume":"11","author":"Chen","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.ctrv.2021.102180_b0280","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2021.102180_b0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102180_b0290","unstructured":"A Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Administered in Combination With Nivolumab (BMS-936558) With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer (NCT03336216). clinicaltrials.gov; 2020."},{"key":"10.1016\/j.ctrv.2021.102180_b0295","unstructured":"Five Prime Therapeutics Provides Update on Phase 2 Trial of Cabiralizumab Combined with Opdivo\u00ae in Pancreatic Cancer, http:\/\/investor.fiveprime.com\/news-releases\/news-release-details\/five-prime-therapeutics-provides-update-phase-2-trial, 2020(accessed 5 March 2021)."},{"key":"10.1016\/j.ctrv.2021.102180_b0300","unstructured":"Cabiralizumab Misses Primary End Point in Phase II Trial of Advanced Pancreatic Cancer, https:\/\/www.targetedonc.com\/view\/cabiralizumab-misses-primary-end-point-in-phase-ii-trial-of-advanced-pancreatic-cancer; 2021 (accessed 5 March 2021)."},{"key":"10.1016\/j.ctrv.2021.102180_b0305","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1200\/JCO.2020.38.4_suppl.637","article-title":"Randomized phase III study of FOLFOX alone and with pegilodecakin as second-line therapy in patients with metastatic pancreatic cancer (SEQUOIA)","volume":"38","author":"Hecht","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102180_b0310","doi-asserted-by":"crossref","unstructured":"Renouf DJ, Knox JJ, Kavan P, Jonker D, Welch S, Couture F, et al. LBA65 The Canadian Cancer Trials Group PA.7 trial: Results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC). Ann Oncol 2020;31:S1195. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.2300.","DOI":"10.1016\/j.annonc.2020.08.2300"},{"key":"10.1016\/j.ctrv.2021.102180_b0315","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.3748\/wjg.v24.i20.2137","article-title":"Immune therapies in pancreatic ductal adenocarcinoma: where are we now?","volume":"24","author":"Hilmi","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ctrv.2021.102180_b0320","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA -mutated metastatic pancreatic cancer","author":"Golan","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2021.102180_b0325","unstructured":"Lynparza\u00ae. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lynparza; 2020 (accessed 5 March 2021)."},{"key":"10.1016\/j.ctrv.2021.102180_b0330","unstructured":"Lynparza\u00ae. Product information. Swissmedic, http:\/\/www.swissmedicinfo.ch; 2020 (accessed 5 March 2021)."},{"key":"10.1016\/j.ctrv.2021.102180_b0335","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.19.02931","article-title":"Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA\/PALB2 mutation","volume":"38","author":"O\u2019Reilly","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102180_b0340","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00280-015-2788-6","article-title":"Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma","volume":"76","author":"Fogelman","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ctrv.2021.102180_b0345","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of Canada clinical trials group","volume":"25","author":"Moore","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102180_b0350","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000502844","article-title":"Cetuximab in pancreatic cancer therapy: a systematic review and meta-analysis","volume":"98","author":"Forster","year":"2020","journal-title":"Oncology"},{"key":"10.1016\/j.ctrv.2021.102180_b0355","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.00590","article-title":"Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma","author":"Van Cutsem","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102180_b0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00124","article-title":"Palbociclib in patients with pancreatic and biliary cancer with CDKN2A alterations: results from the targeted agent and profiling utilization registry study","author":"Al Baghdadi","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"340\u2013353","key":"10.1016\/j.ctrv.2021.102180_b0365","article-title":"CDK4\/6 inhibitors impair recovery from cytotoxic chemotherapy in pancreatic adenocarcinoma","volume":"37","author":"Salvador-Barbero","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2021.102180_b0370","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41575-019-0109-y","article-title":"Molecular subtypes of pancreatic cancer","volume":"16","author":"Collisson","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2021.102180_b0375","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S1470-2045(20)30074-7","article-title":"Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial","volume":"21","author":"Pishvaian","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2021.102180_b0380","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctrv.2021.102180_b0385","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1158\/2159-8290.CD-18-0349","article-title":"Organoid profiling identifies common responders to chemotherapy in pancreatic cancer","volume":"8","author":"Tiriac","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2021.102180_b0390","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/s41588-019-0566-9","article-title":"Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution","volume":"52","author":"Chan-Seng-Yue","year":"2020","journal-title":"Nat Genet"},{"key":"10.1016\/j.ctrv.2021.102180_b0395","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2021.102180_b0400","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.apsb.2019.03.002","article-title":"Targeting the untargetable KRAS in cancer therapy","volume":"9","author":"Liu","year":"2019","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.ctrv.2021.102180_b0405","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1200\/JCO.2019.37.15_suppl.3003","article-title":"Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRAS G12C inhibitor, in advanced solid tumors","volume":"37","author":"Fakih","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102180_b0410","doi-asserted-by":"crossref","DOI":"10.3390\/cancers8040045","article-title":"KRAS mutant pancreatic cancer: no lone path to an effective treatment","volume":"8","author":"Zeitouni","year":"2016","journal-title":"Cancers"},{"key":"10.1016\/j.ctrv.2021.102180_b0415","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRASG12C inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2021.102180_b0420","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0959-8049(20)31077-7","article-title":"KRYSTAL-1: activity and safety of adagrasib (MRTX849) in patients with colorectal cancer (CRC) and other solid tumors harboring a KRAS G12C mutation","volume":"138","author":"Johnson","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2021.102180_b0425","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.1158\/1078-0432.CCR-19-0191","article-title":"NRG1 gene fusions are recurrent, clinically actionable gene rearrangements in KRAS wild-type pancreatic ductal adenocarcinoma","volume":"25","author":"Jones","year":"2019","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ctrv.2021.102180_b0430","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2017.35.15_suppl.2522","article-title":"First-in-human phase 1\/2 study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3: final phase 1 data and preliminary activity in HER2+ metastatic breast cancer (MBC)","volume":"35","author":"Alsina","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102180_b0435","doi-asserted-by":"crossref","first-page":"viii223","DOI":"10.1093\/annonc\/mdy282.048","volume":"29","author":"Alsina","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2021.102180_b0440","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ebiom.2019.01.037","article-title":"Cytosolic 5\u2032-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites","volume":"40","author":"Patzak","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ctrv.2021.102180_b0445","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ebiom.2019.02.008","article-title":"Drug resistance in pancreatic cancer: New player caught in act","volume":"40","author":"Capurso","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ctrv.2021.102180_b0450","doi-asserted-by":"crossref","first-page":"21613","DOI":"10.18632\/oncotarget.25085","article-title":"Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review","volume":"9","author":"Sheahan","year":"2018","journal-title":"Oncotarget"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737221000281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737221000281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:24:16Z","timestamp":1759656256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737221000281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":90,"alternative-id":["S0305737221000281"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2021.102180","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment landscape of metastatic pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2021.102180","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102180"}}